Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Recombinant Human Alpha-Fetoprotein
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : AbSci
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Alpha Cancer Technologies to License AbSci's SoluPro Strain for the Expression of Alpha-Fetoprotein
Details : Under the terms of the agreement AbSci will prepare the hAFP producing E. coli strain for transfer to Alpha Cancer Technologies' CMO of choice for commercial production.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : Recombinant Human Alpha-Fetoprotein
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : AbSci
Deal Size : Undisclosed
Deal Type : Licensing Agreement